TB continuum of care |
This dashboard presents indicators relevant for the second step of the continuum of TB care and prevention
Presenting to health facilities and being diagnosed
C.1. Rapid testing for TB
C.1.1 Percentage of people with presumptive TB tested with a WHO-recommended rapid diagnostic test, 2023
C.1.2 Number of diagnostic tests performed for TB using WHO-recommended rapid diagnostic tests (WRDs)
C.1.3 Number of positive results among the diagnostic tests performed using WRDs
C.1.4 Percentage of tests for TB that were positive among diagnostic tests performed using WRDs
C.1.5 Percentage of districts that monitored test positivity rate, 2023
C.1.6 Percentage of people diagnosed with a new episode of TB who were initially tested with a WRD
C.1.7 Percentage of districts in which all facilities have a TB diagnostic algorithm requiring use of a WHO-recommended rapid diagnostic test as the initial diagnostic test for all people with presumptive TB
C.1.8 Percentage of primary health-care facilities with access to WHO-recommended rapid diagnostic tests, 2023
C.1.9 Percentage of tests required to test all people with presumptive TB that can be performed with existing instruments, 2023
C.1.10 Percentage of sites providing molecular WHO-recommended rapid diagnostics testing for TB with annual error rates of 5% or less, 2023
C.1.11 Percentage of laboratories that achieved a turn-around time within 48 hours for at least 80% of samples received for WHO-recommended rapid diagnostic testing, 2023
C.2. Bacteriological confirmation
C.2.1 Number of people diagnosed with a new episode of pulmonary TB whose disease was bacteriologically confirmed
C.2.2 Percentage of people diagnosed with a new episode of pulmonary TB whose disease was bacteriologically confirmed
C.2.3 Percentage people diagnosed with new episode of bacteriologically confirmed and clinically diagnosed pulmonary tested with a WHO-recommended rapid diagnostic test, 2023
C.3. Testing for TB drug resistance
C.3.1 Number of people diagnosed with bacteriologically confirmed pulmonary TB tested for rifampicin susceptibility
C.3.2 Percentage of people diagnosed with bacteriologically confirmed pulmonary TB tested for rifampicin susceptibility
C.3.3 Number of people diagnosed with bacteriologically confirmed pulmonary TB that is resistant to rifampicin
C.3.4 Percentage of people tested for RR-TB who were resistant to rifampicin
C.4. Testing for HIV
C.4.1 Percentage HIV tested and HIV positive
Diagnosed, not notified
C.5. Notifications
C.5.1 Percentage of people with TB who are diagnosed by public and private providers, but not notified to the NTP (level of underreporting), YEAR
C.5.2 Rate Ratio 0-4 to 5-14 year olds (new episode, all forms TB)
C.5.3 Contribution of public-private mix and public-public mix initiatives to case notifications of people diagnosed with TB (absolute number)
C.5.4 Contribution of public-private mix and public-public mix initiatives to case notifications of people diagnosed with TB (%)
C.6. Risk factors for underreporting
C.6.1 Odds ratio for underreporting by age group, YEAR
C.6.2 Odds ratio for underreporting by sex, YEAR
C.6.3 Odds ratio for underreporting by case type, YEAR
C.6.4 Odds ratio for underreporting by site of TB disease, YEAR
C.6.5 Odds ratio for underreporting by HIV status, YEAR
C.6.6 Odds ratio for underreporting by sector, YEAR
Metadata
Glossary and definitions
Molecular WHO-recommended rapid diagnostic test | Diagnostic tests approved
by WHO that employs molecular-based techniques for the diagnosis of tuberculosis (TB). |
---|---|
Bacteriologically confirmed | A person from whom a bacteriological specimen is positive by a WHO recommended rapid diagnostic test, culture, or smear microscopy. |
New episode of TB | A person with TB disease who has either
(i.e. any case apart from a re-registered case). |
Pulmonary TB | A person with TB disease involving the lung parenchyma or the tracheobronchial tree. |
Public-private mix | Public-private mix refers to engagement by the NTP with private sector providers of TB care. Examples include private individual and institutional providers, the corporate or business sector, mission hospitals, nongovernmental organizations and faith-based organizations. |
Public-public mix | Public-public mix refers to engagement by the NTP with public health sector providers of TB care that are not under the direct purview of the NTP. Examples include public hospitals, public medical colleges, prisons and detention centres, military facilities and public health insurance organizations. |
Testing for drug susceptibility | In vitro testing of a strain of M. Tuberculosis complex using either: 1) molecular, genotypic techniques to detect resistance-conferring mutations; or 2) phenotypic methods to determine susceptibility to a medicine. |
Rifampicin-resistant TB (RR-TB) | A person with TB disease who is infected with a strain of M. Tuberculosis complex that is resistant to rifampicin. |
HIV positive | A person with TB disease who has a documented positive result from HIV testing before, at the time of TB diagnosis or during the TB episode. |
Proportion of people with TB who are diagnosed by public and private providers, but not notified to NTP | Number of cases diagnosed with TB and not reported to the national TB surveillance system (often managed by an NTP) divided by the total number of diagnosed cases (the sum of reported and unreported cases) expressed by percentage. |
Rate ratio 0-4 to 5-14 years old | New and recurrent TB notification rate among children aged 0-4 years compared to those among aged 5-15 years. |
Odds ratio of under-reporting | The risk factors of under-reporting within TB inventory study are measured as odd of under-reporting among exposed (females, children, HIV positive, extra-pulmonary localization, clinically diagnosed, detected by private care provider) over the odds of under-reporting among not exposed (males, adults, HIV-negative, pulmonary localization, bacteriologically confirmed, detected by public health care provider). |
Copyright and licensing
Copyright | Attribution 4.0 International (CC BY 4.0) |
---|---|
License | The World Health Organization (“WHO”) encourages public access and use of the data that it collects and publishes on its web site data.who.int. The data are organized in datasets and made available in machine-readable format (“Datasets”). The Datasets have been compiled from data provided by WHO’s Member States under the WHO policy on the use and sharing of data collected by WHO in Member States outside the context of public health emergencies. Use of the data derived from the Datasets, which may appear in formats such as tables and charts, is also subject to these Terms and Conditions. Datasets may include data describing the Dataset called “Metadata”. If any datasets are credited to a source other than WHO, then those materials are not covered by these Terms and Conditions, and permission should be sought from the source provided. You are responsible for determining if this is the case, and if so, you are responsible for obtaining any necessary permission from the sources indicated. The risk of claims resulting from infringement of any third-party-owned component in the materials rests solely with you. You may use our application programming interfaces (“APIs”) to facilitate access to the Datasets, whether through a separate web site or through another type of software application. By using the Datasets or any presentations of data derived from them, or by using our APIs in connection with the Datasets, you agree to be bound by these Terms and Conditions, as may be amended from time to time by WHO at its sole discretion. Unless specifically indicated otherwise, these Datasets are provided to you under a Creative Commons Attribution 4.0 International License (CC BY 4.0), with the additional terms below. The basic terms applicable to the CC BY 4.0 license may be accessed here. By downloading or using the Datasets, you agree to comply with the terms of the CC BY 4.0 license, as well as the following mandatory and binding addition: Any dispute relating to the interpretation or application of this license shall, unless amicably settled, be subject to conciliation. In the event of failure of the latter, the dispute shall be settled by arbitration. The arbitration shall be conducted in accordance with the modalities to be agreed upon by the parties or, in the absence of agreement, with the UNCITRAL Arbitration Rules. The parties shall accept the arbitral award as final. |
Permission type | Publicly accessible |
Prohibited uses | You shall not attempt to de-anonymise the Datasets or use the Datasets in a manner that falsifies or misrepresents their content. You shall not, in connection with your use of the Datasets published on data.who.int, state or imply that WHO endorses, or is affiliated with, you, or that WHO endorses your use of data.who.int, or any content, output, or analysis resulting from or related to the data.who.int, or any entity, organization, company, product or services. |
Citation | World Health Organization 2025 data.who.int, WHO TB dashboard [Dashboard]. https://data.who.int/dashboards/tuberculosis/ |
Disclaimer | WHO reserves the right at any time and from time to time to modify or discontinue, temporarily or permanently, the Datasets, or any means of accessing or utilizing the Datasets with or without prior notice to you. Maps All references to Kosovo should be understood to be in the context of the United Nations Security Council resolution 1244 (1999). A dispute exists between the Governments of Argentina and the United Kingdom of Great Britain and Northern Ireland concerning sovereignty over the Falkland Islands (Malvinas). The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters. All reasonable precautions have been taken by WHO to verify the accuracy of the Datasets. However, the Datasets are being provided without warranty of any kind, either expressed or implied. You will be solely responsible for your use of the Datasets. In no event shall WHO be liable for any damages arising from such use. For full disclaimers, terms of use and your indemnification of WHO, please visit Terms and Conditions. |